报价延迟最少15分钟:2026/01/07 03:39 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.12 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-49.75/-3.92
|
|
企业价值
8.43M
|
| 资产负债 |
|
每股账面净值
-13.00
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. |
